Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Ozanimod: a better or just another S1P receptor modulator?
Sphingosine-1-phosphate receptor inhibition prevents denervation-induced dendritic atrophy.
The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper.
Conditioned Medium from the Stem Cells of Human Exfoliated Deciduous Teeth Ameliorates Experimental Autoimmune Encephalomyelitis.
Impact of oral health in patients with multiple sclerosis and epilepsy: A survey in a neurology clinic.
Bilirubin-induced neural impairment: A special focus on myelination, age-related windows of susceptibility and associated co-morbidities.
Microglia: Multitasking Specialists of the Brain.
Exploring meanings of illness causation among those severely affected by multiple sclerosis: a comparative qualitative study of Black Caribbean and White British people.
A single dose of a neuron-binding human monoclonal antibody improves brainstem NAA concentrations, a biomarker for density of spinal cord axons, in a model of progressive multiple sclerosis.
Chronic cerebrospinal venous insufficiency and multiple sclerosis: a comprehensive meta-analysis of case-control studies.
Disease modifying therapies in multiple sclerosis: Could a baseline thyroid check-up drive the therapeutic choice between interferon-β and glatiramer acetate?
miR-20b Suppresses Th17 Differentiation and the Pathogenesis of Experimental Autoimmune Encephalomyelitis by Targeting RORγt and STAT3.
Localisation of citrullinated proteins in normal appearing white matter and lesions in the central nervous system in multiple sclerosis.
Defining a role for laquinimod in multiple sclerosis.
Ocular side effects of drugs used in the treatment of multiple sclerosis.
Role of TRIF Small Interference RNA (siRNA) in Chronic Experimental Allergic Encephalomyelitis (EAE).
An Individualized Yoga Programme for Multiple Sclerosis: A Case Study.
Weight status in persons with multiple sclerosis: implications for mobility outcomes.
Switching Therapies in Multiple Sclerosis.
Subsequent brain tumors in patients with autoimmune disease.
Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging.
Disability caused by multiple sclerosis is associated with the number of extra cranial venous stenoses: possible improvement by venous angioplasty. Results of a prospective study.
Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels.
C16 peptide shown to prevent leukocyte infiltration and alleviate detrimental inflammation in acute allergic encephalomyelitis model.
On the role of natural killer cells in neurodegenerative diseases.
Pages
« first
‹ previous
…
498
499
500
501
502
503
504
505
506
…
next ›
last »